BioregulatorResearch
Retinalamin
Also known as: Retinal bioregulator
A pharmaceutical-grade retinal polypeptide delivered via parabulbar injection for diabetic retinopathy and age-related macular degeneration.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~2 hours
Typical Dose
5 mg daily (parabulbar injection)
Administration
Parabulbar injection
Mechanism of Action
Organ-specific retinal peptide fraction that halts photoreceptor death and promotes retinal tissue regeneration.
Key Research Areas
bioregulatorretinadiabetic retinopathyAMD
Frequently Asked Questions
What is Retinalamin?▾
A pharmaceutical-grade retinal polypeptide delivered via parabulbar injection for diabetic retinopathy and age-related macular degeneration.
How does Retinalamin work?▾
Organ-specific retinal peptide fraction that halts photoreceptor death and promotes retinal tissue regeneration.
What is the recommended dosage for Retinalamin?▾
The typical research dosage is 5 mg daily (parabulbar injection), administered via Parabulbar injection. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Retinalamin?▾
The half-life of Retinalamin is approximately ~2 hours. This affects dosing frequency and timing in research protocols.
Is Retinalamin FDA approved?▾
Retinalamin is currently classified as "Research" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about Retinalamin is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.